Fortrea Financial Ratios
NASDAQ: FTREHealthcareBiotechnologyUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Fortrea ratio analysis
Fortrea earned a net margin of -36.2% in FY 2025, down from -12.2% a year earlier. Gross margin was 18.5% compared with a median of 20.3% over the prior 4 years. Return on equity reached -175.0%, meaning Fortrea generated -1.75 dollars of profit for every dollar of shareholders' equity.
Debt-to-equity stood at 1.87 versus 0.83 the year before, and the current ratio was 0.98. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Fortrea financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Price / sales | — | 0.64 | 1.09 | — | — |
| Price / book | — | 1.27 | 1.81 | — | — |
| Gross margin | 18.5% | 19.8% | 20.8% | 25.5% | 19.8% |
| Operating margin | -32.0% | -6.0% | 1.1% | 6.6% | 3.7% |
| Net margin | -36.2% | -12.2% | -0.9% | 6.6% | 3.2% |
| Free cash flow margin | 3.2% | 8.8% | 4.5% | 1.0% | 4.7% |
| Return on equity (ROE) | -175.0% | -24.1% | -1.5% | 5.6% | 3.0% |
| Return on assets (ROA) | -36.3% | -9.2% | -0.6% | 4.3% | — |
| Debt / equity | 1.87 | 0.83 | 0.93 | 0.00 | — |
| Current ratio | 0.98 | 1.00 | 1.61 | 1.78 | — |
| Revenue growth | 1.0% | -5.1% | 0.2% | -7.2% | — |
| EPS growth | — | — | -113.9% | 90.0% | — |